The Living Heart Project of Dassault Systèmes allows virtual experiments on medical devices and even drugs since last year. There are now 130 partners in this project and the collaboration with the FDA could increase this number. The next step for Dassault Systèmes is to plan medical trials with virtual patients. With the demonstration of efficiency of this process, future medical trails could be very different from today and much more accurate.
Dassault Systèmes today announced a five-year extension of its collaboration with the US Food and Drug Administration (FDA), through which the company will develop a new tool to increase efficiency in the regulatory review process.As part of its work with the FDA, the company is exploring the use of heart simulation as a source of digital evidence and developing virtual patients based on computational modeling and simulation to improve the efficiency of clinical trials.
Source: The Living Heart: FDA renews contract with Dassault to evaluate 3D simulation, virtual patients